Back to Search
Start Over
Over the counter low-dose cannabidiol: A viewpoint from the ACRE Capacity Building Group.
- Source :
-
Journal of psychopharmacology (Oxford, England) [J Psychopharmacol] 2022 Jun; Vol. 36 (6), pp. 661-665. Date of Electronic Publication: 2021 Aug 03. - Publication Year :
- 2022
-
Abstract
- Amidst growing global acceptance of medicinal cannabinoids as a potential therapeutic interest in cannabidiol (CBD) is increasing. In Australia in 2020, a government inquiry examined the barriers that the public are experiencing in accessing medicinal cannabis. A number of recommendations to improve access were made. In response to these recommendations, the Australian therapeutics regulatory authority down-scheduled CBD from Prescription Only (Schedule 4) to Pharmacist Only (Schedule 3). As a group of early to mid-career researchers of the Australian Centre for Cannabinoid Clinical and Research Excellence (ACRE), we propose some considerations in relation to over-the-counter availability of CBD and opportunities to improve knowledge about its potential therapeutic benefits alongside its increased uptake.
Details
- Language :
- English
- ISSN :
- 1461-7285
- Volume :
- 36
- Issue :
- 6
- Database :
- MEDLINE
- Journal :
- Journal of psychopharmacology (Oxford, England)
- Publication Type :
- Academic Journal
- Accession number :
- 34344208
- Full Text :
- https://doi.org/10.1177/02698811211035394